围手术期应用丹参酮ⅡA磺酸钠对冠心病心绞痛介入治疗患者术后预后的影响

doi:10.3969/j.issn.1006-6233.2017.08.015

Abstract
Figure/Table
References
Related Citation (12)

Download: PDF (1370 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effect of application of sodium tanshinone IIA sulfonate in perioperative period on the prognosis of patients with coronary heart disease (CHD) and angina pectoris after interventional therapy. Methods: 94 cases of CHD with coronary intervention (PCI) treated by coronary intervention (PCI) were divided into the control group and the study group with 47 cases each by random number table in March 2013 to March 2017. The control group was treated with conventional therapy such as clopidogrel and aspirin during the perioperative period. The study group was treated with routine treatment with tanshinone IIA A sulfonate. Blood rheology, platelet membrane glycoproteins, inflammatory factors and brain natriuretic peptide (BNP) levels, short-term prognosis and adverse drug reactions were compared between the two groups before and after treatment. Results: After treatment, the blood rheological indicators were significantly decreased in the two groups (P < 0.05), and the blood viscosity, high / low shear blood viscosity, the maximum platelet aggregation rate and fibrinogen levels were significantly lower in the study group than in the control group (P < 0.05); the levels of CD62p, CD63, PAC-1, CRP, IL-6 and BNP were significantly decreased, and CD42b levels were increased significantly in the two groups (P < 0.05), and the above levels in the study group were lower than those in the control group (P < 0.05). The recurrence rate of angina pectoris in the study group was significantly lower than that in the control group during follow-up period (P < 0.05), and there was no significant difference in the incidence of adverse drug reactions between the two groups (P > 0.05). Conclusion: The application of sodium tanshinone IIA sulfonate in perioperative period of PCI can effectively improve the blood rheological indexes, play an antiplatelet role, promote the recovery of tissue injury, relieve inflammation, and improve the cardiac function in patients with coronary heart disease and angina pectoris, without increasing adverse reactions, and the short-term prognosis is good.

Key words： Perioperative period Sodium tanshinone IIA sulfonate Coronary heart disease Angina pectoris

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.08.015 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I8/1284

[1] 李路军.以牙痛为首发表现的冠心病九例误诊讨论[J].临床误诊误治,2016,29(5):10~12.
[2] 第一届全国内科学术会议心血管病组.关于冠状动脉性心脏病命名及诊断标准的建议[J].中华心血管病杂志,1981,9(1):75~76.
[3] 刘玉茹,卢艳秋,徐慧敏,等.冠脉CT造影对冠心病患者治疗与心血管病相关因素控制影响的研究[J].中国CT和MRI杂志,2016,14(7):49~51.
[4] 王诗瑶,董波.温阳活血方联合心痛贴对冠心病心绞痛病人高敏C反应蛋白的影响[J].中西医结合心脑血管病杂志,2016,14(8):806~809.
[5] 夏世杰,尹扬光,方颖,等.阿托伐他汀联合丹参酮ⅡA磺酸钠注射液对冠心病患者心绞痛影响[J].河北医学,2016,22(7):1067~1070.
[6] 段丙军,林德智,熊富权,等.通心络胶囊治疗气虚血瘀型冠心病心绞痛的疗效及作用机制[J].疑难病杂志,2016,15(10):1065~1068.
[7] 唐文,谭建玲,贾亮亮,等.益心舒胶囊辅助治疗冠心病心绞痛有效性的Meta分析[J].中国药房,2016,27(3):351~353.
[8] 段凯强,肖华,左建华,等.全真一气汤合并失笑散联合常规西药治疗冠心病心绞痛的应用价值分析[J].空军医学杂志,2016,32(5):341~344.
[9] 方玲.尼可地尔片对冠心病心绞痛患者血栓前状态及血管内皮功能的影响[J].血栓与止血学,2016,22(2):137~139.
[10] 张锋,杨柳青.曲美他嗪治疗老年冠心病稳定性心绞痛临床观察[J].临床医药文献杂志:电子版,2016,3(36):7236~7237.
[11] 王小渠,李伯庆.中西医结合治疗冠心病不稳定型心绞痛的临床研究[J].成都医学院学报,2015,10(4):473~474.
[12] 孙莉萍.冠心病合并糖耐量减低患者血小板参数与超敏C反应蛋白的相关性研究[J].医学临床研究,2016,33(3):444~446.
[13] 郑刚.丹参酮Ⅱ_A磺酸钠注射液临床应用专家建议[J].中华老年心脑血管病杂志,2015,17(12):1261~1264.
[14] 陈蕾,任耀龙,杨磊.自拟活血通络方治疗冠心病PCI术后心绞痛[J].长春中医药大学学报,2016,32(2):330~332.
[15] 柴光德.中医药治疗冠心病心绞痛的研究进展[J].世界临床药物,2016,37(6):432~432.
[16] 裴树亮,赵卫国.参附注射液防治老年粗隆间骨折合并冠心病心绞痛患者围术期不良预后的临床研究[J].中国药物与临床,2015,15(9):1335~1337.
[17] 马晓聪,李建橡,许明东,等.丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛疗效和安全性的Meta分析[J].世界科学技术-中医药现代化,2015,17(9):1766~1774.
[18] 黄芳,李玲,徐宏彬.丹参酮Ⅱ_A磺酸钠治疗冠心病心绞痛疗效的系统评价[J].中国药房,2015,26(9):1225~1228.
[19] 黄菁菁,张伟霞,杨婉花.丹参酮Ⅱ_A磺酸钠治疗冠心病心绞痛的临床观察[J].中国药房,2016,27(2):219~222.